Penetrium Bioscience Inc.

As of June 30, 2026, Penetrium Bioscience Inc. carries a market capitalization of 296.89B, placing it among publicly traded companies globally. Its enterprise value stands at 301.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Penetrium Bioscience Inc. has 57.99M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 33.46, and the price-to-book ratio stands at 12.94.

These figures are as of June 30, 2026. The EV/Sales ratio of 36.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 301.83B versus a market cap of 296.89B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Penetrium Bioscience Inc. maintains a current ratio of 0.49, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 23.74, indicating elevated leverage, while an interest coverage ratio of -6.30 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Penetrium Bioscience Inc. posted a negative return on equity (ROE) of -104.28, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -54.28, reflecting losses generated across the asset base. The company generates approximately 68.26M in revenue per employee across its workforce of 122.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Penetrium Bioscience Inc. recorded 128.96M in income tax expense. The company reported a pretax loss of -16.23B and -16.36B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Penetrium Bioscience Inc.'s stock has gained approximately 92.66% over the past 52 weeks. The 50-day moving average sits at 5,751.20, while the 200-day moving average is 6,996.48.

Over the twelve months ended June 30, 2026, Penetrium Bioscience Inc. generated 8.34B in revenue and converted that into -16.36B in net income, yielding earnings per share of -289.93. EBITDA reached -5.70B, while operating income came in at -6.70B.

As of June 30, 2026, Penetrium Bioscience Inc. holds 500.99M in cash and equivalents against 5.44B in total debt, resulting in a net debt position of 4.58B. Total book value stands at 22.94B, with working capital of -4.78B providing operational flexibility.

Penetrium Bioscience Inc. produced -4.12B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -157.61M in capital expenditures, free cash flow totaled -4.28B - equivalent to -78.48 per share.

Over the twelve months ended June 30, 2026, Penetrium Bioscience Inc. posted a gross margin of 6.09, reflecting its pricing power and cost economics. The operating margin of -80.30 and net profit margin of -196.11 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.52, meaning Penetrium Bioscience Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Penetrium Bioscience Inc.'s most recent stock split took place on June 29, 2026 with a 496:525 split ratio.

As of June 30, 2026, Penetrium Bioscience Inc. has an Altman Z-Score of 14.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.